Eli Lilly and Company $LLY Shares Sold by Goelzer Investment Management Inc.

Goelzer Investment Management Inc. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 542,867 shares of the company’s stock after selling 1,625 shares during the quarter. Eli Lilly and Company makes up approximately 27.1% of Goelzer Investment Management Inc.’s investment portfolio, making the stock its largest position. Goelzer Investment Management Inc. owned 0.06% of Eli Lilly and Company worth $583,408,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. 10Elms LLP grew its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. raised its position in Eli Lilly and Company by 0.7% during the 4th quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after purchasing an additional 10 shares during the last quarter. Bridgewater Advisors Inc. raised its position in Eli Lilly and Company by 0.3% during the 3rd quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock worth $3,018,000 after purchasing an additional 11 shares during the last quarter. Manske Wealth Management lifted its holdings in Eli Lilly and Company by 2.5% during the 3rd quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after buying an additional 11 shares during the period. Finally, Guardian Partners Inc. lifted its holdings in Eli Lilly and Company by 0.3% during the 3rd quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after buying an additional 12 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Rothschild & Co Redburn upped their target price on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a report on Monday, January 26th. Finally, UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.26.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to buy Centessa Pharmaceuticals in a cash deal that pays $38/share upfront with contingent value rights that can lift the total to roughly $7.8 billion; the acquisition brings Centessa’s OX2R agonist sleep?wake program (lead asset cleminorexton) into Lilly’s neuroscience pipeline and reduces reliance on a single franchise for future growth. Lilly to acquire Centessa press release
• Positive Sentiment: Lilly expanded its AI drug?discovery partnership (Insilico/Insilico Medicine) in a deal worth up to ~$2.75 billion, aiming to speed molecule discovery and lower R&D costs — a strategic move that could increase pipeline throughput and long?term earnings visibility. Lilly extends Insilico partnership (Reuters)
• Neutral Sentiment: Market reaction to the Centessa deal sent Centessa (CNTA) shares sharply higher and drove options activity; that reflects dealcertainty and investor demand for sleep?med assets but is more about the target than an immediate P&L boost for Lilly. Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
• Neutral Sentiment: Analyst/market notes were mixed: some firms keep buy ratings (Guggenheim maintained buy while trimming its target slightly) — a sign analysts view the strategic moves as supportive but remain cautious on valuation. Guggenheim price-target note (Benzinga)
• Negative Sentiment: Competitive risk: Novo Nordisk launched a multi?month subscription for Wegovy (cash?pay patients) to undercut prices and win share in the obesity/GLP?1 market — increased pricing competition could pressure Lilly’s high?margin GLP?1 cash sales over time. Novo launches Wegovy subscription (CNBC)

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $918.12 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The business has a 50-day moving average price of $1,001.75 and a two-hundred day moving average price of $966.95. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a market cap of $867.46 billion, a P/E ratio of 40.01, a PEG ratio of 1.03 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the business earned $5.32 EPS. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.